NCT05577923View on ClinicalTrials.gov

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

September 1, 2024

Study Completion Date

March 1, 2026

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Trastuzumab

8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks

DRUG

pyrotinib

Pyrotinib 320mg, PO daily, continuously

DRUG

Dalpiciclib

Dalpiciclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks

DRUG

fulvestrant

Fulvestrant will be given intramuscle at the dose of 500 mg every 4 weeks (with an additional 500 mg dose given two weeks after the initial dose.

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT05577923 - Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower) | Biotech Hunter | Biotech Hunter